2 results about "Viral resistance" patented technology

This invention belongs to the field of biomedical technology and relates to a novel use of chlorpropamide, particularly its use in the preparation of antiviral drugs for influenza. This invention verifies the antiviral efficacy of chlorpropamide using a host-targeting strategy. Experiments have confirmed that chlorpropamide exhibits low cytotoxicity, can target the early stages of influenza virus replication, inhibits viral protein and gene expression, regulates the host inflammatory response, and significantly inhibits the replication of H1N1 PR8 influenza virus in vitro. Chlorpropamide is a major component of commercially available hypoglycemic drugs, with a well-established safety profile, short development cycle, and low cost. It can circumvent the bottleneck of viral resistance and has significant clinical value in the preparation of antiviral drugs for influenza.

This invention belongs to the field of biomedical technology, specifically disclosing a scorpion-derived polypeptide for combating influenza virus and its applications. The scorpion-derived polypeptide has the amino acid sequence shown in SEQ ID NO:1, or is a functional variant obtained by substitution, deletion, and / or addition of one or more amino acids from the same sequence, retaining its anti-influenza virus activity. The scorpion-derived polypeptide provided by this invention can significantly inhibit the proliferation of influenza A virus and substantially reduce the expression levels of viral RNA and protein within a non-cytotoxic concentration range. It also effectively reduces viral load and inflammatory factor levels in mice infected with influenza A virus, exhibiting excellent anti-influenza A virus activity and being less likely to induce viral resistance. This invention provides a novel, highly efficient, and low-toxicity bioactive molecule for influenza prevention and control, which can be applied to the development of anti-influenza drugs.